Purpose

The purpose of the study is to understand the origins of differential response to beta-blockers in African-Americans and may provide insight regarding racial differences in cardiovascular risk.

Conditions

Eligibility

Eligible Ages
Between 18 Years and 40 Years
Eligible Genders
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • 18 to 40 years - Blood pressure less than 140/90 mm Hg - Able to perform exercise capacity test - BMI 18-25 kg/m2 - Willing to adhere to study drug

Exclusion Criteria

  • History of cardiovascular disease or use of medications for CVD - History of hypertension or use of BP lowering medications - Blood pressure less than 100/60 mm Hg - Heart rate less than 60 beats/min - Depression - Diabetes or use of anti-diabetic medications - Renal disease (eGFR < 60ml/min/1.73m2) - Current or prior smokers - Pregnant or use of Hormone Replacement Therapy (HRT) or oral contraceptives (OCP) or steroids

Study Design

Phase
Phase 2
Study Type
Interventional
Allocation
Non-Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Other
Masking
Single (Outcomes Assessor)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
African-American
Healthy lean (BMI 18-25 kg/m2) African-American participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
  • Other: Exercise capacity VO2 max determination
    Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
  • Dietary Supplement: Standardized meals
    Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
  • Other: Exercise challenge
    Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
  • Drug: Metoprolol Succinate ER
    Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.
Active Comparator
Caucasians (White)
Healthy lean (BMI 18-25 kg/m2) white participants will be enrolled and each will undergo a physical exam and screening tests to determine participants' eligibility. Participants will perform exercise capacity VO2 max determination test, followed by 3 days of standardized meals and exercise challenge test. After exercise challenge test, all the participants will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day.
  • Other: Exercise capacity VO2 max determination
    Each participant's maximal oxygen capacity will be determined using a modified Bruce treadmill protocol.
  • Dietary Supplement: Standardized meals
    Participants will consume the standardized study diet for 3 days provided by the clinical research unit's metabolic kitchen (at UAB).
  • Other: Exercise challenge
    Each participant will walk at 70 % of his/her VO2max for 20 minutes on treadmill.
  • Drug: Metoprolol Succinate ER
    Each participant will receive metoprolol succinate starting at 50mg/day, titrated bi-weekly up to 200 mg/day for total duration of 6 weeks.

Recruiting Locations

University of Alabama at Birmingham
Birmingham, Alabama 35294

More Details

Status
Recruiting
Sponsor
University of Alabama at Birmingham

Study Contact

Nirav Patel, MD
205-934-6058
npatel@uabmc.edu

Detailed Description

The heart is an endocrine organ. The natriuretic peptides are hormones produced in the heart and are secreted in response to increased wall stress in atria and ventricles. The principal circulating NPs are Atrial Natriuretic Peptide (ANP) and B-type Natriuretic Peptide (BNP). The endocrine actions of NPs are natriuresis and dilatation of peripheral arteries. The NPs concentrations are elevated in heart failure (HF) and hypertension (HTN) due to volume and pressure overload. Therefore, NPs are used as diagnostic and prognostic markers in heart failure. However, NPs role in healthy individuals is not known. Previous studies have shown that reduced NP levels are associated with a greater risk of HTN. Moreover, African-Americans have lower resting NP levels than Caucasians. We hypothesize that relative NP deficiency in African American compared to Caucasian has the potential to contribute to increase risk of all-cause mortality, HTN, HF and its sequelae. Evidence from multiple clinical trials has positioned beta-blockers as a standard heart failure therapy. Beta-blocker therapy leads to increased NP levels and suppression of Renin-aldosterone-angiotensin system (RAAS) system. Suppression of renin levels by beta-blockers has been shown as a potential mechanism of benefit in HF. However, study shows that beta-blockers are less effective in African-Americans compared to Caucasians in HF treatment. So, the investigators have proposed a pilot study to look for race-based differences in the NP and RAAS response to metoprolol in healthy individuals. Additionally, exercise has been reported to increase NP levels. ANP increases more than BNP with exercise. But there is no data of NP changes in African-American with exercise. So the investigators have proposed a sub-study of race-based difference in ANP and BNP response to exercise. 40 African-American and 40 Caucasians normotensive or pre-hypertensive (healthy) individuals will be enrolled.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.